Calcitonin Blood Test Explained: What It Measures and Why It's Ordered

The calcitonin blood test is a laboratory measurement of a single peptide hormone in serum or plasma. In the clinical literature it appears almost entirely in one context: the detection, staging and follow-up of medullary thyroid carcinoma (MTC), a tumour arising from the thyroid's calcitonin-producing cells. This page summarises what the analyte is, how the measurement is performed, why the published literature describes clinicians ordering it, and what reviews and case series have reported about high, low and undetectable values. This page is for educational purposes only and is not medical advice; consult a licensed physician or the ordering clinician to interpret any laboratory result.

What calcitonin is and where it comes from

Calcitonin is a 32-amino-acid peptide hormone secreted by the parafollicular C cells of the thyroid gland. Because those cells are the dominant source, circulating calcitonin tracks C-cell mass and C-cell activity, which is the biological basis for its use as a tumour marker. A 2015 review on calcitonin as a biomarker described the hormone as the reference circulating marker for medullary thyroid carcinoma and reviewed its role across diagnosis and monitoring (PMID 26494386). A 2021 review of diagnostic challenges in medullary thyroid carcinoma similarly positioned calcitonin as the central biochemical test in the diagnostic pathway (PMID 33878761).

Calcitonin belongs to the family of calcium-regulating peptides, and the hormone is discussed in the broader literature on disordered calcium handling in malignancy; a 2013 German-language review of tumour-induced hypercalcaemia surveyed how calcium disturbances in cancer patients were evaluated and classified (PMID 23934479). In routine adult practice, however, the published rationale for ordering a calcitonin level is oncological rather than a direct assessment of calcium metabolism.

What the test measures

The analyte is the intact calcitonin monomer in a blood sample. Modern laboratories use two-site immunometric ("sandwich") immunoassays that are designed to capture the mature hormone rather than its precursors or fragments, and reviews of MTC diagnosis have emphasised that assay generation and calibration materially affect the numbers reported (PMID 23955938). Reference intervals are assay-specific and differ by sex and by platform, which is one reason the literature repeatedly cautions against comparing values generated on different systems (PMID 26494386).

Basal calcitonin

The default form of the test is a single unstimulated (basal) measurement on a routine blood draw. Reviews of the diagnostic workup describe basal calcitonin as the first-line biochemical step, with a markedly elevated basal value carrying much stronger diagnostic weight than a borderline one (PMID 33878761).

Stimulated calcitonin

When basal values fall into an equivocal range, the literature describes provocative testing in which a secretagogue is infused and calcitonin is sampled serially. A 2013 paper in Experimental and Clinical Endocrinology & Diabetes set out a procedural proposal for standardised calcium-stimulated calcitonin measurement, addressing how the test should be performed and sampled so that results are comparable between centres (PMID 23430575). Reviews of newer diagnostic acquisitions have also discussed where stimulation testing fits once sensitive basal assays are available (PMID 27808486).

Calcitonin in needle-washout fluid

Beyond blood, calcitonin has been measured in the fluid used to rinse a fine-needle aspiration needle after sampling a nodule or lymph node. A 2017 review of thyroglobulin, calcitonin and PTH measurement in FNA washout fluids described this as an adjunct to cytology, with the washout concentration interpreted alongside the cytological findings rather than against a serum reference range (PMID 27802177).

Why clinicians order a calcitonin test, as described in the literature

Published reviews group the indications into a small number of recurring scenarios.

The screening question has been the most debated. A 2018 recommendation paper in Deutsche Medizinische Wochenschrift addressed calcitonin screening in nodular goitre and argued the case for measuring calcitonin during the initial workup of nodular thyroid disease, while acknowledging the controversy over cost and false-positive results (PMID 30060274). A 2014 appraisal of medullary thyroid cancer diagnosis reviewed the same debate and the comparative performance of calcitonin against cytology in nodule evaluation (PMID 23955938).

What published studies associate with high calcitonin levels

The association most consistently reported is with medullary thyroid carcinoma and with its precursor state, C-cell hyperplasia. A 2015 biomarker review described calcitonin concentrations as broadly reflecting tumour burden in MTC, which is why the marker is used both at diagnosis and for serial follow-up after surgery (PMID 26494386). The 2021 diagnostic-challenges review noted that very high basal values are far more specific for MTC than mild elevations, and that mildly raised results in particular require a careful differential rather than immediate diagnostic conclusions (PMID 33878761).

Reviews also stress that calcitonin is not an exclusive product of thyroid C cells. The 2014 appraisal of MTC diagnosis discussed non-MTC causes of raised calcitonin among the reasons that a single elevated result is not treated as diagnostic on its own (PMID 23955938), and a 2017 review of novel diagnostic acquisitions examined how additional markers and procedures were being used to resolve ambiguous elevations (PMID 27808486). No published source supports interpreting a number in isolation, and none of the work cited here provides a threshold that can be applied to an individual outside clinical assessment.

Normal, low or undetectable calcitonin: what the literature reports

A normal calcitonin does not, by itself, exclude C-cell malignancy. A 2015 systematic review in Clinical Chemistry and Laboratory Medicine collected published cases of serum-calcitonin-negative medullary thyroid carcinoma and examined their clinical and pathological features, establishing that the phenomenon is real but uncommon (PMID 25781697). A 2024 systematic review in Gland Surgery revisited the question across 101 reported cases of calcitonin-negative medullary thyroid carcinoma and discussed the diagnostic difficulties these tumours created (PMID 39544965). A 2018 case report in Diagnostic Cytopathology described a calcitonin-negative mixed medullary-follicular carcinoma that had initially been called medullary thyroid carcinoma on fine-needle aspiration cytology, and reviewed the comparable literature (PMID 29524315).

Low or undetectable values are also expected after complete surgical removal of calcitonin-producing tissue, and the 2015 biomarker review described post-operative measurement as a standard element of follow-up for exactly that reason (PMID 26494386).

Assay and interpretation caveats: What Studies Report

Several recurring technical issues appear across the reviews:

• Assay dependence. Researchers writing the 2014 diagnostic appraisal emphasised that calcitonin results are method-dependent and that values from different immunoassays are not interchangeable (PMID 23955938).
• Borderline elevations. The 2021 review reported that mildly elevated basal calcitonin is the hardest result to act on and described the additional steps used to clarify it (PMID 33878761).
• Standardisation of stimulation testing. The 2013 procedural proposal was written specifically because calcium-stimulated calcitonin testing had been performed inconsistently between centres (PMID 23430575).
• False negatives. The 2015 and 2024 systematic reviews both documented histologically confirmed medullary thyroid carcinoma with negative serum calcitonin, a scenario the authors reported as a genuine diagnostic pitfall (PMID 25781697, PMID 39544965).
• Washout interpretation. The 2017 FNA-washout review noted that washout-fluid measurement requires its own interpretive framework and is not read against serum ranges (PMID 27802177).

Markers studied alongside calcitonin

Because calcitonin alone has limitations, the literature has examined complementary analytes. A 2021 study in Clinical Chemistry and Laboratory Medicine measured circulating pro-gastrin-releasing peptide (ProGRP) in patients with medullary thyroid carcinoma and evaluated its behaviour as a circulating marker in that population (PMID 33860650). The 2017 review of novel acquisitions in MTC diagnosis surveyed the wider set of biochemical, cytological and molecular tools that had been proposed to supplement calcitonin measurement (PMID 27808486).

How results are handled clinically

Across the sources above, the consistent pattern is that calcitonin is interpreted as one input among several — history and family history, imaging, cytology, genetic findings where relevant, and the trend of serial values — rather than as a standalone verdict. A 2021 review described the diagnostic pathway as an integration of biochemistry with imaging and pathology (PMID 33878761), and the 2018 nodular-goitre recommendation framed calcitonin screening as a step within a defined workup rather than an isolated test (PMID 30060274).

Nothing on this page constitutes an interpretation of any individual result, a reference range, or a threshold for action. Questions about a specific calcitonin value, the assay used, repeat testing or any follow-up investigation belong with the clinician who ordered the test.

References

• Diagnostic Challenges of Medullary Thyroid Carcinoma (Oncology, 2021)
• [Tumor-induced hypercalcemia] (Der Internist, 2013)
• Serum calcitonin negative medullary thyroid carcinoma: a systematic review of the literature (Clinical Chemistry and Laboratory Medicine, 2015)
• Medullary thyroid cancer diagnosis: an appraisal (Head & Neck, 2014)
• Serum calcitonin negative mixed medullary-follicular carcinoma initially diagnosed as medullary thyroid carcinoma by fine-needle aspiration cytology: A case report and review of the literatures (Diagnostic Cytopathology, 2018)
• [Recommendation for Calcitonin Screening in Nodular Goiter] (Deutsche Medizinische Wochenschrift, 2018)
• Circulating pro-gastrin releasing peptide (ProGRP) in patients with medullary thyroid carcinoma (Clinical Chemistry and Laboratory Medicine, 2021)
• Calcitonin as Biomarker for the Medullary Thyroid Carcinoma (Recent Results in Cancer Research, 2015)
• Calcium stimulated calcitonin measurement: a procedural proposal (Experimental and Clinical Endocrinology & Diabetes, 2013)
• Measurement of thyroglobulin, calcitonin, and PTH in FNA washout fluids (Clinical Chemistry and Laboratory Medicine, 2017)
• Diagnostic challenges in calcitonin negative medullary thyroid carcinoma: a systematic review of 101 cases (Gland Surgery, 2024)
• Novel acquisitions in the diagnosis of medullary thyroid carcinoma (Minerva Endocrinologica, 2017)